Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells

[1]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[2]  A. Schally,et al.  Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild‐type p53 and decrease in p21 and mutant p53 proteins , 2012, The Prostate.

[3]  H. Atmaca,et al.  Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels , 2012, Journal of Cancer Research and Clinical Oncology.

[4]  Sarfraz Ahmad,et al.  Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts , 2012, Expert review of anticancer therapy.

[5]  Yuquan Wei,et al.  Proapoptotic Protein Smac Mediates Apoptosis in Cisplatin-resistant Ovarian Cancer Cells When Treated with the Anti-tumor Agent AT101* , 2011, The Journal of Biological Chemistry.

[6]  J. Holmlund,et al.  Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  L. Sequist,et al.  Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Robert Brown,et al.  Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer , 2010, Therapeutic advances in medical oncology.

[9]  X. Zhong,et al.  Epigenetics of ovarian cancer: from the lab to the clinic. , 2010, Gynecologic oncology.

[10]  L. Moretti,et al.  AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  P. Harnett,et al.  Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience , 2010, Asia-Pacific journal of clinical oncology.

[12]  H. Atmaca,et al.  Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination , 2010, Molecular Biology Reports.

[13]  H. Atmaca,et al.  Targeting apoptosis in the hormone‐ and drug‐resistant prostate cancer cell line, DU‐145, by gossypol/zoledronic acid combination , 2009, Cell biology international.

[14]  H. Atmaca,et al.  Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. , 2009, European cytokine network.

[15]  D. Matei,et al.  Minireview: epigenetic changes in ovarian cancer. , 2009, Endocrinology.

[16]  H. Verheul,et al.  Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[17]  H. Atmaca,et al.  Regulation of growth factors in hormone‐ and drug‐resistant prostate cancer cells by synergistic combination of docetaxel and octreotide , 2009, BJU international.

[18]  B. Somer,et al.  An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer , 2009, Clinical Cancer Research.

[19]  Jui‐I Chao,et al.  Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. , 2008, Chemico-biological interactions.

[20]  P. Petit,et al.  Cysteine 62 of Bax Is Critical for Its Conformational Activation and Its Proapoptotic Activity in Response to H2O2-induced Apoptosis* , 2008, Journal of Biological Chemistry.

[21]  Liz Y. Han,et al.  Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-κB Pathway , 2007, Clinical Cancer Research.

[22]  John C Reed,et al.  Drug Insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms , 2006, Nature Clinical Practice Oncology.

[23]  John Mohan,et al.  Caspase-2 Triggers Bax-Bak-dependent and -independent Cell Death in Colon Cancer Cells Treated with Resveratrol* , 2006, Journal of Biological Chemistry.

[24]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[25]  Y. Luqmani.  Mechanisms of Drug Resistance in Cancer Chemotherapy , 2005, Medical Principles and Practice.

[26]  Shaomeng Wang,et al.  Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL , 2005, Molecular Cancer Therapeutics.

[27]  Robert Brown,et al.  The epigenetics of ovarian cancer drug resistance and resensitization. , 2004, American journal of obstetrics and gynecology.

[28]  John Calvin Reed,et al.  The c‐IAP‐1 and c‐IAP‐2 proteins are direct inhibitors of specific caspases , 1997, The EMBO journal.

[29]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[30]  G. Hannon,et al.  Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage , 1996, Current Biology.

[31]  J C Reed,et al.  The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. , 1995, Oncogene.

[32]  J. Whang‐Peng,et al.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. , 1983, Cancer research.

[33]  J. Thigpen.  A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q) , 2011 .

[34]  H. Bartelink,et al.  AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. , 2009, Radiation oncology.

[35]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.